Researchers at the University of North Carolina found that a once-weekly injection of Ozempic could cut cravings at its ...

Ozempic (semaglutide) is a subcutaneous injection used in people with type 2 diabetes. It may cause mild side effects, such as abdominal pain, or more serious side effects, such as diabetic ...

Results of a placebo-controlled trial support prior observational findings that GLP-1 agonists can help reduce alcohol ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

Administered as a once-weekly subcutaneous injection, Ozempic not only helps control blood glucose levels but also reduces ...

Semaglutide for weight loss is given as a subcutaneous injection. This means a very thin needle is inserted into the layer of fatty tissue just under the skin. Brand-name semaglutide (Wegovy and ...

A new study suggests that semaglutide, a drug commonly used for diabetes and obesity, may also help reduce alcohol consumption.

The phase 3b STEP UP trial in more than 1,400 patients compared a 7.2mg weekly subcutaneous injection of semaglutide to the standard 2.6mg weekly dose sold as Wegovy or a matched placebo.

Research reveals semaglutide's effectiveness in decreasing alcohol consumption and cravings, highlighting its potential for treating alcohol use disorder.

Randomized, placebo-controlled trial finds that low-dose semaglutide reduces amount of alcohol consumption, alcohol cravings, and heavy drinking days. Reductions in cigarettes per day were also seen.

Semaglutide is a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor mimicking its activity. GLP-1 is an incretin hormone and enterogastrone that stimulates insulin ...